Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Candel Therapeutics (CADL) EPS (Weighted Average and Diluted) (2021 - 2025)

Candel Therapeutics' EPS (Weighted Average and Diluted) history spans 3 years, with the latest figure at -$0.38 for Q4 2023.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 123.53% to -$0.38 in Q4 2023 year-over-year; TTM through Dec 2023 was -$1.3, a 103.12% decrease, with the full-year FY2025 number at -$0.72, up 58.62% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.38 in Q4 2023 for Candel Therapeutics, down from -$0.29 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for CADL hit a ceiling of $0.51 in Q4 2021 and a floor of -$1.46 in Q2 2021.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$0.33 across 3 years, with a median of -$0.3 in 2022.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): soared 90.41% in 2022 and later tumbled 900.0% in 2023.
  • Tracing CADL's EPS (Weighted Average and Diluted) over 3 years: stood at $0.51 in 2021, then plummeted by 133.33% to -$0.17 in 2022, then plummeted by 123.53% to -$0.38 in 2023.
  • Business Quant data shows EPS (Weighted Average and Diluted) for CADL at -$0.38 in Q4 2023, -$0.29 in Q3 2023, and -$0.33 in Q2 2023.